Eupraxia Pharmaceuticals’ (EPRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a research note published on Friday,Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock.

Several other research analysts also recently commented on the stock. Wall Street Zen raised shares of Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. Leede Financial raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $11.67.

Eupraxia Pharmaceuticals Stock Performance

Shares of NASDAQ EPRX opened at $8.12 on Friday. Eupraxia Pharmaceuticals has a fifty-two week low of $2.68 and a fifty-two week high of $8.74. The company has a market cap of $292.00 million, a price-to-earnings ratio of -9.33 and a beta of 1.21. The business’s 50 day moving average price is $6.58 and its 200-day moving average price is $5.89.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. Sell-side analysts predict that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Several large investors have recently modified their holdings of the business. Quadrature Capital Ltd bought a new position in shares of Eupraxia Pharmaceuticals during the second quarter valued at approximately $61,000. TCI Wealth Advisors Inc. purchased a new stake in Eupraxia Pharmaceuticals during the third quarter worth $65,000. Integrated Wealth Concepts LLC bought a new stake in Eupraxia Pharmaceuticals during the 3rd quarter valued at $71,000. Bank of America Corp DE increased its holdings in shares of Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after acquiring an additional 10,059 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Eupraxia Pharmaceuticals by 593.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after acquiring an additional 16,017 shares during the period.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.